Immunome Inc. financial data

Symbol
IMNM on Nasdaq
Industry
Pharmaceutical Preparations
Location
18702 N. Creek Parkway, Suite 100, Bothell, WA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 747 % +205%
Debt-to-equity 16.8 % -95.2%
Return On Equity -140 % +26.9%
Return On Assets -120 % -181%
Operating Margin -3.13K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.4M shares +46.1%
Common Stock, Shares, Outstanding 60.4M shares +395%
Entity Public Float 75.5M USD +121%
Common Stock, Value, Issued 6K USD +500%
Weighted Average Number of Shares Outstanding, Basic 60.2M shares +393%
Weighted Average Number of Shares Outstanding, Diluted 60.2M shares +393%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.1M USD -18.4%
Research and Development Expense 91.3M USD +416%
General and Administrative Expense 30.5M USD +102%
Operating Income (Loss) -317M USD -1301%
Net Income (Loss) Attributable to Parent -305M USD -1291%
Earnings Per Share, Basic -8.1 USD/shares -348%
Earnings Per Share, Diluted -8.1 USD/shares -348%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 156M USD +71.6%
Assets, Current 244M USD +167%
Property, Plant and Equipment, Net 7.17M USD +512%
Operating Lease, Right-of-Use Asset 2.39M USD +592%
Other Assets, Noncurrent 3.2M USD
Assets 257M USD +176%
Accounts Payable, Current 3.52M USD +26.3%
Employee-related Liabilities, Current 3.31M USD +141%
Contract with Customer, Liability, Current 9.68M USD -42.9%
Liabilities, Current 39.5M USD +71%
Contract with Customer, Liability, Noncurrent 2.21M USD -76.6%
Deferred Income Tax Liabilities, Net 378K USD +1119%
Operating Lease, Liability, Noncurrent 2.46M USD
Other Liabilities, Noncurrent 1.34M USD +2061%
Liabilities 42M USD -51.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 70K USD
Retained Earnings (Accumulated Deficit) -436M USD -235%
Stockholders' Equity Attributable to Parent 215M USD +3437%
Liabilities and Equity 257M USD +176%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.2M USD -146%
Net Cash Provided by (Used in) Financing Activities 219M USD +645326%
Net Cash Provided by (Used in) Investing Activities -37.2M USD -35024%
Common Stock, Shares Authorized 300M shares +50%
Common Stock, Shares, Issued 60.4M shares +395%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 171M USD +610%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 156M USD +71.6%
Deferred Tax Assets, Valuation Allowance 39.8M USD +30.1%
Deferred Tax Assets, Gross 40.2M USD +31.2%
Operating Lease, Liability 2.72M USD
Payments to Acquire Property, Plant, and Equipment 2.16M USD +1942%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -305M USD -982%
Lessee, Operating Lease, Liability, to be Paid 3.72M USD
Operating Lease, Liability, Current 257K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 841K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 881K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 633K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 37K USD 0%
Additional Paid in Capital 650M USD +377%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 157K USD +67%
Deferred Tax Assets, Net of Valuation Allowance 378K USD +1119%
Share-based Payment Arrangement, Expense 13.2M USD +180%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%